Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid Hemorrhage | Zendy

Robert M. Starke | Zendy; Grace H. Kim | Zendy; Andres Fernandez | Zendy; Ricardo J. Komotar | Zendy; Zachary L. Hickman | Zendy; Marc L. Otten | Zendy; Andrew F. Ducruet | Zendy; Christopher P. Kellner | Zendy; David Hahn | Zendy; Markus Chwajol | Zendy; Stephan A. Mayer | Zendy; E. Sander Connolly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of a Protocol for Acute Antifibrinolytic Therapy on Aneurysm Rebleeding After Subarachnoid Hemorrhage

Author(s) -

Robert M. Starke,

Grace H. Kim,

Andres Fernandez,

Ricardo J. Komotar,

Zachary L. Hickman,

Marc L. Otten,

Andrew F. Ducruet,

Christopher P. Kellner,

David Hahn,

Markus Chwajol,

Stephan A. Mayer,

E. Sander Connolly

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.506097

Subject(s) - medicine , antifibrinolytic , subarachnoid hemorrhage , anesthesia , aneurysm , placebo , aminocaproic acid , surgery , pulmonary embolism , randomized controlled trial , tranexamic acid , blood loss , alternative medicine , pathology

epsilon-Aminocaproic acid (EACA) is an antifibrinolytic agent used to prevent rebleeding in aneurysmal subarachnoid hemorrhage. Although studies have found that a decrease in rebleeding with long-term antifibrinolytic therapy is offset by an increase in ischemic deficits, more recent studies have indicated that early, short-term therapy may be beneficial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research